Gianluca Tomasello

Summary

Affiliation: Faculty of Medicine

Publications

  1. doi Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib
    Gianluca Tomasello
    Institut Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Crit Rev Oncol Hematol 75:110-21. 2010
  2. ncbi Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen
    Gianluca Tomasello
    Medical Oncology Division, Azienda Istituti Ospitalieri di Cremona, Italy
    Tumori 96:48-53. 2010
  3. ncbi A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
    Matteo Dalla Chiesa
    Medical Oncology, 2Surgery Division, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy
    Tumori 93:244-7. 2007
  4. doi Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer
    Rodolfo Passalacqua
    Divisione di Medicina e Oncologia Medica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy
    Cancer Immunol Immunother 59:553-61. 2010
  5. doi Jumping higher: is it still possible? The ALTTO trial challenge
    Gianluca Tomasello
    Institute Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Expert Rev Anticancer Ther 8:1883-90. 2008
  6. doi Emerging combination therapies to overcome resistance in EGFR-driven tumors
    Margherita Ratti
    Medical Oncology Unit, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy
    Anticancer Drugs 25:127-39. 2014
  7. ncbi Immunotherapy options in metastatic renal cell cancer: where we are and where we are going
    Rodolfo Passalacqua
    Istituti Ospitalieri, Department of Internal Medicine, Medical Oncology Division, Viale Concordia 1, 26100, Cremona, Italy
    Expert Rev Anticancer Ther 6:1459-72. 2006

Collaborators

Detail Information

Publications7

  1. doi Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib
    Gianluca Tomasello
    Institut Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Crit Rev Oncol Hematol 75:110-21. 2010
    ..This article reviews the epidemiology, current treatment options and recent advances in the field, with a focus on HER2-positive disease and the emerging role of lapatinib for the treatment and prevention of brain metastases...
  2. ncbi Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen
    Gianluca Tomasello
    Medical Oncology Division, Azienda Istituti Ospitalieri di Cremona, Italy
    Tumori 96:48-53. 2010
    ....
  3. ncbi A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
    Matteo Dalla Chiesa
    Medical Oncology, 2Surgery Division, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy
    Tumori 93:244-7. 2007
    ..The aim of this study was to evaluate chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI regimen) in metastatic gastric cancer...
  4. doi Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer
    Rodolfo Passalacqua
    Divisione di Medicina e Oncologia Medica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy
    Cancer Immunol Immunother 59:553-61. 2010
    ..88; 95% CI 0.60-1.31; p = 0.54). Toxicity was mainly limited to WHO grades 1 or 2. Chronic maintenance immunotherapy after disease progression is feasible, but does not significantly increase OS or the TFPTD...
  5. doi Jumping higher: is it still possible? The ALTTO trial challenge
    Gianluca Tomasello
    Institute Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Expert Rev Anticancer Ther 8:1883-90. 2008
    ..Overall, 8000 patients will be enrolled worldwide...
  6. doi Emerging combination therapies to overcome resistance in EGFR-driven tumors
    Margherita Ratti
    Medical Oncology Unit, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy
    Anticancer Drugs 25:127-39. 2014
    ..Here, we describe some of the mechanisms of resistance to EGFR inhibitors and review the main innovations attempting to overcome these drawbacks. ..
  7. ncbi Immunotherapy options in metastatic renal cell cancer: where we are and where we are going
    Rodolfo Passalacqua
    Istituti Ospitalieri, Department of Internal Medicine, Medical Oncology Division, Viale Concordia 1, 26100, Cremona, Italy
    Expert Rev Anticancer Ther 6:1459-72. 2006
    ..Future research will not only need to make every effort to optimize the use of the new molecules and to define their efficacy precisely, but also to consider how to integrate these drugs with the traditional immunotherapy...